公开(公告)号：MX387728B

公开(公告)日：2025-03-18

申请号：MX2020004501

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/437 ,  A61P35/00

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：MX380504B

公开(公告)日：2025-03-12

申请号：MX2016012396

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/02

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：NZ753024A

公开(公告)日：2020-08-28

申请号：NZ75302411

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating diffuse large B-cell lymphoma (DLBCL) in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：AU2017272271A1

公开(公告)日：2018-01-04

申请号：AU2017272271

申请日：2017-12-07

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：CA3110966A1

公开(公告)日：2013-04-25

申请号：CA3110966

申请日：2012-10-19

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: G01N33/48 ,  A61K31/519 ,  A61P35/00

Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：CA3022256A1

公开(公告)日：2011-12-08

申请号：CA3022256

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K9/48 ,  A61K39/395 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3007788A1

公开(公告)日：2011-12-08

申请号：CA3007788

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K39/395 ,  A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3007787A1

公开(公告)日：2011-12-08

申请号：CA3007787

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：AU2024266757A1

公开(公告)日：2024-12-12

申请号：AU2024266757

申请日：2024-11-21

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：AU2021286264A1

公开(公告)日：2022-01-06

申请号：AU2021286264

申请日：2021-12-14

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.